-
Company number
-
0819.236.165
-
Location
- Rue Sainte-Gertrude(Piét.) 5 Jodoigne 1370
-
Founding date
- Founded in 03-10-2009
-
Juridical situation
- Normale toestand
-
Juridical form
- Besloten Vennootschap
-
Type of enterprise
- Rechtspersoon
Very high risk
High risk
Average
Low risk
Very low risk
| Financial ratios | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Equity |
€
446K
22.01%
|
€
366K
18.58%
|
€
308K
20.01%
|
€
257K
|
| Profit |
€
112K
42.59%
|
€
79K
52.71%
|
€
51K
33.32%
|
€
39K
|
| EBITDA |
€
114K
29.19%
|
€
88K
9.43%
|
€
81K
29.44%
|
€
62K
|
| Gross margin |
€
114K
29.04%
|
€
89K
9.47%
|
€
81K
29.88%
|
€
62K
|
| Debt |
€
45K
47.22%
|
€
30K
18.62%
|
€
26K
-29.99%
|
€
36K
|
| Cash |
€
247K
41.54%
|
€
174K
19.73%
|
€
146K
17.78%
|
€
124K
|
Directors
All directorsActivities according to NACEBEL codes
Activities
VAT Activities
Social Security Activities
Publications 10
All publicationsMe. - Comptes Annuels 30.06.2016, App 18.11.2016, Dpt 12.12.2016 16699-0047-011
19/12/2016
Me. - Comptes Annuels 30.06.2015, App 20.11.2015, Dpt 04.12.2015 15682-0291-011
10/12/2015
Me. - Comptes Annuels 30.06.2014, App 21.11.2014, Dpt 19.12.2014 14701-0539-012
31/12/2014
Me. - Comptes Annuels 30.06.2013, App 15.11.2013, Dpt 05.12.2013 13681-0026-010
16/12/2013
Me. - Comptes Annuels 30.06.2012, App 16.11.2012, Dpt 10.12.2012 12663-0141-010
18/12/2012
Me. - Comptes Annuels 30.06.2011, App 25.11.2011, Dpt 13.12.2011 11639-0026-009
21/12/2011
Me. - Comptes Annuels 30.06.2010, App 04.12.2010, Dpt 27.12.2010 10647-0387-010
03/01/2011
Similar companies
Show allFrequently asked questions
The VAT number of PHARM-AD is BE0819.236.165.
PHARM-AD was founded in 03-10-2009.
The official address of PHARM-AD is Rue Sainte-Gertrude(Piét.) 5 Jodoigne 1370 .
The juridical form of PHARM-AD is Besloten Vennootschap.
The legal situation of PHARM-AD is Normale toestand.
The annual revenue of PHARM-AD is €0.
Sources
Ready to start?
Find out the financial situation of potential customers, suppliers or business partners by consulting official information and key figures.
